Company intelligence / Profile preview

Igentify

New York City, New York, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~58
Development stage: Commercial

Overview

Igentify’s Digital Genetic Assistant has demonstrated clinical utility in studies such as an Expanded Carrier Screening trial, where it reduced the need for face-to-face or telephonic counseling by automating result delivery. In one study with couples undergoing ECS, only about 5.4% requested traditional counseling after using the system, while over 90% preferred receiving results digitally. The company’s NIPT and PGx offerings are commercially available as of March 2024.

Therapeutic areas: OtherRare DiseasesWomen's Health
Modalities: Device (software-based digital platform)Non-pharmacological therapy (genetic counseling/education)
Industry: Molecular Diagnostics

Partnerships

IlluminaThermo Fisher Scientific

Beyond the preview

Go deeper on Igentify.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Igentify.

Explore the full profile